Anti-inflammatory Probiotics in Cognitive Functioning

NCT ID: NCT07165977

Last Updated: 2025-09-17

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

NA

Total Enrollment

110 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-01-25

Study Completion Date

2026-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this study is to explore the potential impact of an anti-inflammatory probiotic mixture of psychobiotics including Bifidobacterium longum Rosell®-175 and Lactobacillus helveticus Rosell®-52 on cognitive functions in older adults following either pro-inflammatory or anti-inflammatory diets. According to recent findings, even short-term exposure to foods with pro- or anti-inflammatory properties may lead to corresponding negative or beneficial effects on cognitive functioning .

The main questions this study aims to answer are:

* How important is the initial dietary pattern for observing possible beneficial effects of probiotic supplementation? (Diet as a potential moderator)
* How important is the initial state of the gut microbiota for observing possible beneficial effects of probiotic supplementation? (Microbiota as a potential moderator)
* Is it possible to improve or slow down the decline in cognitive functions associated with aging with probiotic supplementation?
* Can probiotic supplementation counteract the negative effects of pro-inflammatory dietary patterns?

The investigators will compare probiotic to a placebo (a look-alike substance that contains no active ingredients) to determine whether probiotic is effective in enhancing cognitive function.

Participants:

* Take a probiotic or placebo capsule daily for 3 months
* Undergo a crossover after 3 months - those who initially took probiotics will switch to the placebo, and vice versa
* Visit SWPS University for screening (T0), baseline assessments before beginning supplementation (T1), and follow-up assessments at 3 months (T2) and 6 months (T3). The T2 visit occurs just before the crossover.
* Complete neuropsychological testing, questionnaires, and EEG recordings during the T1, T2, and T3 visits.
* Provide stool samples for gut microbiota analysis at the T1, T2, and T3 visits.
* Maintain their usual dietary habits throughout the study.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Memory Decline Cognitive Decline Cognitive Aging

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Randomized, double-blind, and placebo-controlled study
Primary Study Purpose

PREVENTION

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Anti-inflammatory diet + probiotic first

This is a group of participants whose everyday dietary pattern was assessed as anti-inflammatory based on the Shivappa et al. (2014) equation, and who will receive probiotics during the first 3 months of the study.

Group Type EXPERIMENTAL

Probiotic Supplementation (Bifidobacterium longum Rosell®-175 & Lactobacillus helveticus Rosell®-52) then placebo

Intervention Type DIETARY_SUPPLEMENT

Each participant will take a probiotic mixture containing Bifidobacterium longum Rosell®-175 \& Lactobacillus helveticus Rosell®-52 and excipients: potato starch, magnesium stearate, and the capsule shell of hydroxypropyl methylcellulose. (Sanprobi Stress; Sanprobi sp. z o.o., sp.k., Szczecin, Poland) for 3 months.

* Dosage: One capsule per day, containing 3 × 10⹠(3 billion) CFU\*.
* Instructions: Take before 1:00 PM. Do not consume hot drinks immediately after taking the capsule.

After completion of the first phase, each participant will take a probiotic containing only the excipients, i.e. maize starch, maltodextrins, and the capsule shell for another 3 months.

* Dosage: One capsule per day.
* Instructions: Take before 1:00 PM. Do not consume hot drinks immediately after taking the capsule.
* CFU = Colony Forming Units

Anti-inflammatory diet + placebo first

This is a group of participants whose everyday dietary pattern was assessed as anti-inflammatory based on the Shivappa et al. (2014) equation, and who will receive placebo during the first 3 months of the study.

Group Type EXPERIMENTAL

Placebo Supplementation then Probiotic Supplementation (Bifidobacterium longum Rosell®-175 & Lactobacillus helveticus Rosell®-52)

Intervention Type DIETARY_SUPPLEMENT

Each participant will take a probiotic containing only the excipients, i.e. maize starch, maltodextrins, and the capsule shell for 3 months.

* Dosage: One capsule per day.
* Instructions: Take before 1:00 PM. Do not consume hot drinks immediately after taking the capsule.

After completion of the first phase, each participant will take a probiotic mixture containing Bifidobacterium longum Rosell®-175 \& Lactobacillus helveticus Rosell®-52 and excipients: potato starch, magnesium stearate, and the capsule shell of hydroxypropyl methylcellulose. (Sanprobi Stress; Sanprobi sp. z o.o., sp.k., Szczecin, Poland) for another 3 months.

* Dosage: One capsule per day, containing 3 × 10⹠(3 billion) CFU\*.
* Instructions: Take before 1:00 PM. Do not consume hot drinks immediately after taking the capsule.
* CFU = Colony Forming Units

Pro-inflammatory diet + probiotic first

This is a group of participants whose everyday dietary pattern was assessed as pro-inflammatory based on the Shivappa et al. (2014) equation, and who will receive probiotics during the first 3 months of the study.

Group Type EXPERIMENTAL

Probiotic Supplementation (Bifidobacterium longum Rosell®-175 & Lactobacillus helveticus Rosell®-52) then placebo

Intervention Type DIETARY_SUPPLEMENT

Each participant will take a probiotic mixture containing Bifidobacterium longum Rosell®-175 \& Lactobacillus helveticus Rosell®-52 and excipients: potato starch, magnesium stearate, and the capsule shell of hydroxypropyl methylcellulose. (Sanprobi Stress; Sanprobi sp. z o.o., sp.k., Szczecin, Poland) for 3 months.

* Dosage: One capsule per day, containing 3 × 10⹠(3 billion) CFU\*.
* Instructions: Take before 1:00 PM. Do not consume hot drinks immediately after taking the capsule.

After completion of the first phase, each participant will take a probiotic containing only the excipients, i.e. maize starch, maltodextrins, and the capsule shell for another 3 months.

* Dosage: One capsule per day.
* Instructions: Take before 1:00 PM. Do not consume hot drinks immediately after taking the capsule.
* CFU = Colony Forming Units

Pro-inflammatory diet + placebo first

This is a group of participants whose everyday dietary pattern was assessed as pro-inflammatory based on the Shivappa et al. (2014) equation, and who will receive placebo during the first 3 months of the study.

Group Type EXPERIMENTAL

Placebo Supplementation then Probiotic Supplementation (Bifidobacterium longum Rosell®-175 & Lactobacillus helveticus Rosell®-52)

Intervention Type DIETARY_SUPPLEMENT

Each participant will take a probiotic containing only the excipients, i.e. maize starch, maltodextrins, and the capsule shell for 3 months.

* Dosage: One capsule per day.
* Instructions: Take before 1:00 PM. Do not consume hot drinks immediately after taking the capsule.

After completion of the first phase, each participant will take a probiotic mixture containing Bifidobacterium longum Rosell®-175 \& Lactobacillus helveticus Rosell®-52 and excipients: potato starch, magnesium stearate, and the capsule shell of hydroxypropyl methylcellulose. (Sanprobi Stress; Sanprobi sp. z o.o., sp.k., Szczecin, Poland) for another 3 months.

* Dosage: One capsule per day, containing 3 × 10⹠(3 billion) CFU\*.
* Instructions: Take before 1:00 PM. Do not consume hot drinks immediately after taking the capsule.
* CFU = Colony Forming Units

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Probiotic Supplementation (Bifidobacterium longum Rosell®-175 & Lactobacillus helveticus Rosell®-52) then placebo

Each participant will take a probiotic mixture containing Bifidobacterium longum Rosell®-175 \& Lactobacillus helveticus Rosell®-52 and excipients: potato starch, magnesium stearate, and the capsule shell of hydroxypropyl methylcellulose. (Sanprobi Stress; Sanprobi sp. z o.o., sp.k., Szczecin, Poland) for 3 months.

* Dosage: One capsule per day, containing 3 × 10⹠(3 billion) CFU\*.
* Instructions: Take before 1:00 PM. Do not consume hot drinks immediately after taking the capsule.

After completion of the first phase, each participant will take a probiotic containing only the excipients, i.e. maize starch, maltodextrins, and the capsule shell for another 3 months.

* Dosage: One capsule per day.
* Instructions: Take before 1:00 PM. Do not consume hot drinks immediately after taking the capsule.
* CFU = Colony Forming Units

Intervention Type DIETARY_SUPPLEMENT

Placebo Supplementation then Probiotic Supplementation (Bifidobacterium longum Rosell®-175 & Lactobacillus helveticus Rosell®-52)

Each participant will take a probiotic containing only the excipients, i.e. maize starch, maltodextrins, and the capsule shell for 3 months.

* Dosage: One capsule per day.
* Instructions: Take before 1:00 PM. Do not consume hot drinks immediately after taking the capsule.

After completion of the first phase, each participant will take a probiotic mixture containing Bifidobacterium longum Rosell®-175 \& Lactobacillus helveticus Rosell®-52 and excipients: potato starch, magnesium stearate, and the capsule shell of hydroxypropyl methylcellulose. (Sanprobi Stress; Sanprobi sp. z o.o., sp.k., Szczecin, Poland) for another 3 months.

* Dosage: One capsule per day, containing 3 × 10⹠(3 billion) CFU\*.
* Instructions: Take before 1:00 PM. Do not consume hot drinks immediately after taking the capsule.
* CFU = Colony Forming Units

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Aged 50 or older
* Signed written Informed Consent Form
* Score ≥28 on the Mini-Mental State Examination (MMSE)
* A willingness and motivation to follow the study protocol

Exclusion Criteria

* Regular use of prebiotics, antibiotics, or antifungal medications
* Use of prebiotics, antibiotics, or antifungal medications within the past 3 months
* Diagnosed neurological disorder
* History of head injury with neurological consequences
* Left-handedness
Minimum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Sanprobi Sp. z o. o.

UNKNOWN

Sponsor Role collaborator

National Science Centre, Poland

OTHER_GOV

Sponsor Role collaborator

University of Social Sciences and Humanities, Warsaw

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Aneta Brzezicka

Associate professor, Head of the Neurocognitive Research Center at SWPS University

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

SWPS University

Warsaw, Masovian Voivodeship, Poland

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Poland

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2021/43/O/HS6/02074

Identifier Type: OTHER_GRANT

Identifier Source: secondary_id

Cognition-Probiotic-Microbiota

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Probiotics in Dementia
NCT03847714 COMPLETED NA
Probiotics in Mild Alzheimer's Disease
NCT06181513 RECRUITING EARLY_PHASE1
Effect of Probiotic on Depression
NCT04567147 COMPLETED PHASE1